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Pe are honored to provide readers of the Journal with this
eview of major scientific work published in the field of
nterventional Cardiology in 2007. In addition, we have
ncluded late-breaking trials presented at the American
ollege of Cardiology (ACC), Transcatheter Cardiovascu-
ar Therapeutics, and American Heart Association (AHA)
onferences. We hope that the paper will provide a broad
verview of the field for general cardiologists, as well as a
ramework for more detailed study for those with a specific
nterest in Interventional Cardiology.
CCF/AHA/Society for Cardiovascular
ngiography and Interventions 2007
linical Competence Statement
n update of the 1998 clinical competence statement on
ardiac interventional procedures was published in 2007 (1).
his important document provides recommendations for
ssessment and maintenance of cognitive knowledge and
echnical skills necessary for proficiency in cardiac interven-
ional procedures. The statement has also been expanded to
nclude percutaneous noncoronary interventions, including
ortic and mitral valvuloplasty, atrial septal defect and
atent foramen ovale closure, and alcohol septal ablation.
he document reviews expected success and complication
ates, comorbidities or other risk factors that may be used
or risk adjustment, and the relationships between operator
nd institutional activity and percutaneous coronary inter-
ention (PCI) outcomes. A few key recommendations with
espect to operator volumes include: 1) for PCI, the oper-
tor volume threshold continues to be 75 procedures/year;
) for atrial septal defect/patent foramen ovale closure, a
inimum of 10 cases to gain clinical competence, with a
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008, accepted March 18, 2008.urther 10 procedures/year to maintain competency; 3) for
lcohol septal ablation, a minimum of 10 initial procedures,
nd 6 cases/year thereafter; and 4) for valvuloplasty, a
inimum or 5 to 10 cases with an experienced colleague
efore attempting valvuloplasty independently. For further
etails, readers are encouraged to review the Statement (1).
cute Myocardial Infarction (MI)
acilitated PCI. There has been ongoing interest in the
harmacoinvasive approach to improve outcomes of me-
hanical reperfusion. A small study randomized 41 patients
o receive intracoronary streptokinase (250 ku) versus none
fter primary PCI (2). Two days after PCI, the streptoki-
ase group had better measures of microvascular function
nd improved Thrombolysis In Myocardial Infarction
TIMI) frame count; however, at 6 months there was no
ifference in left ventricular (LV) size or function.
Maioli et al. (3) randomized 210 ST-segment elevation
yocardial infarction (STEMI) patients to receive early
bciximab (in the emergency center) versus late administra-
ion (in cath lab). Patients treated with early abciximab
howed benefits in pre-PCI TIMI flow grade 3 (24% vs.
0%; p  0.01), better frame counts, and blush scores.
oreover, post-PCI ST-segment resolution (50% vs. 35%
f patients; p  0.3) and 1-month improvement in ejection
raction (EF) (8% vs. 6%; p  0.2) favored the early
bciximab group. In contrast, the larger FINESSE (Facili-
ated Intervention With Enhanced Reperfusion Speed to
top Events) trial found no benefit of up-front abciximab
efore PCI (4). The FINESSE trial enrolled 2,452 patients
ithin 4 h of STEMI and randomized them to 1 of 3 arms:
bciximab-facilitated PCI, half-dose retaplase with
bciximab-facilitated PCI, or primary PCI. At 90 days,
here was no difference in the primary composite end point
r individual end points of death, ventricular fibrillation,
ardiogenic shock, or readmission for congestive heart
ailure. However, bleeding complications were increased in
he facilitated arms.
escue PCI. Another meta-analysis of rescue PCI includ-
ng 8 randomized trials was published in 2007 (5). This
onfirmed a previous meta-analysis (6) showing that rescue
CI-treated patients had a trend for lower mortality (7.3%
s. 10.4%; p  0.09) and significant reduction in congestive
h
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Year in Interventional Cardiology June 17, 2008:2355–69eart failure (12.7% vs. 17.8%; p  0.05) and reinfarction
6.1% vs. 10.7%; p  0.04). However, rescue PCI was
ssociated with an increased risk of ischemic stroke and
inor bleeding compared with conservative care.
CI after thrombolysis. The CARESS in AMI (Com-
ined Abciximab Retaplase Stent Study in Acute Myocardial
nfarction) trial (7) treated 600 STEMI patients 75 years in
ge with half-dose reteplase, abciximab, aspirin, and heparin,
hen randomized to immediate transfer for PCI versus transfer
nly for rescue PCI (persistent ST-segment elevation). The
ombined end point of death, MI, or refractory ischemia was
mproved in the immediate PCI group (4.4% vs. 10.7%; p 
.004). The rate of TIMI major or minor bleeding was higher
n the immediate PCI group, but this was not statistically
ignificant. These data support previous trials showing that
mmediate PCI after thrombolysis is beneficial (compared with
onservative care), but did not investigate the role of primary
CI (which was the superior strategy in FINESSE [4] and in
he meta-analysis of 17 facilitated PCI trials) (8).
In the ExTRACT–TIMI 25 (Enoxaparin and Throm-
olysis Reperfusion for Acute Myocardial Infarction Treat-
ent) trial, 4,676 patients underwent PCI after fibrinolytic
herapy (9). Compared to unfractionated heparin, enoxapa-
in was associated with a lower incidence of death or MI
10.7% vs. 13.8%; p  0.001), with no difference in major
leeding.
ime-to-treatment. Brodie et al. used the EMERALD
Enhanced Myocardial Efficacy and Removal by Aspiration
f Liberated Debris) trial to determine the impact of
ime-to-treatment on final infarct size assessed by sestamibi
maging (10). Reperfusion 2 h after symptom onset was
ssociated with a smaller infarct size (2% vs. 11%; p 
.008); however, only 5% of patients were reperfused this
uickly. After 3 h, there was little change in final infarct size
ith increasing delay. Time-to-treatment was more impor-
ant for anterior versus inferior MI. These findings, along
ith data from Nallamothu et al. (11) showing that only
5% of U.S. patients have door-to-balloon time of 90
in, suggest that major changes must occur in the U.S.
ospital systems to improve access and speed to reperfusion.
hot et al. (12) described how a change in hospital policy
emergency department activation of the cath lab) decreased
reatment delay by 30 min and led to a marked increase
rom 28% to 75% in the number of patients being treated
ithin 90 min.
utcomes research. A review of the Solucient database
emonstrated a decline in the rate of hospitalizations for AMI
rom 2002 to 2005 (309 to 226 per 100,000 persons), driven
rimarily by a decrease in transmural MI admissions (13).
Previous studies have demonstrated higher mortality for
omen admitted with AMI. Milcent et al. (14) reviewed
4,389 hospitalizations (30% women) in France in 1999.
omen were older and had more comorbidities, including
alve disease, heart failure, stroke, and diabetes. Crude
ortality was higher in women (14.8% vs. 6.1%; p  v.0001). After adjustment for age and comorbidities,
omen still had a higher mortality.
Similarly, racial differences in the use of revascularization
nd mortality were reported (15). Popescu et al. (15) studied
.2 million Medicare beneficiaries admitted with AMI from
anuary 2000 to June 2005. Rates of revascularization and
ransfer from non-PCI to PCI facilities were lower for black
ersus white patients. Although in-hospital mortality rates
ere similar, long-term mortality was higher for black
atients (15).
Several groups reported on development of regional
ystems for STEMI care. In the RACE (Reperfusion of
cute Myocardial Infarction in North Carolina Emergency
epartments) study, marked improvements in time-to-
eperfusion were observed at both PCI and non-PCI centers
fter implementation of a statewide reperfusion program
16). Henry et al. (17) and Ting et al. (18) described 2
egional systems for transfer of STEMI patients in Minne-
ota. These studies demonstrated that rural hospitals can
riage and successfully treat STEMI patients with mechan-
cal reperfusion with well organized transfer protocols.
Ross et al. (19) reviewed the Medicare database for
37,279 AMI patients admitted from 1994 to 1996 to
etermine the impact of the certificate-of-need (CON)
rogram. These authors found that states with CON
tatutes used revascularization less frequently when equivo-
al indications were present.
djunctive therapies and devices. Results of several trials
valuating pharmacologic adjuncts to mechanical reperfu-
ion were reported in 2007. In the APEX-MI (Assessment
f Pexelizumab in Acute Myocardial Infarction) trial, 5,745
atients undergoing primary PCI were randomized to
eceive intravenous pexelizumab or placebo. There was no
ifference in the incidence of 30-day mortality (4.06% for
exelizumab vs. 3.92% for placebo) (20). Dı´az et al. (21)
eported findings of the OASIS-6 GIK (Organization to
ssess Strategies for Ischemic Syndromes 6–Glucose-Insulin-
otassium) trial, as well as a combined analysis of these data
ith the CREATE-ECLA (Clinical Trial of Metabolic
odulation in Acute Myocardial Infarction Treatment
valuation–Estudios Cardiologicos Latinoamerica). Over-
ll, infusion of glucose-insulin-potassium had no benefit on
urvival or other clinical outcomes. On a positive note, the
-WIND (Japan Working Groups of Acute Myocardial
nfarction for the Reduction of Necrotic Damage by Atrial
atriuretic Peptide or Nicorandil) investigators found that
dministration of intravenous atrial natriuretic peptide in
atients with AMI resulted in a 14% reduction in infarct
ize assessed by creatine kinase release kinetics (22).
The AMIHOT (Acute Myocardial Infarction with Hy-
eroxemic Therapy) trials investigated the use of intracoro-
ary supersaturated oxygen therapy in patients with AMI
23,24). Patients with anterior MI 6 h treated with
upersaturated oxygen had a 25% reduction in infarct size
ompared with the control group (median infarct size 18.5%
s. 25% of the left ventricle; p  0.023).
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Enyzme to Limit Total Infarct Size in Acute Myocardial
nfarction) trial tested 4 escalating doses of KAI-9803 in
atients with anterior wall MI and total occlusion of the left
nterior descending artery (25). Favorable improvements in
T-segment resolution, creatine kinase release kinetics,
yocardial perfusion grade, and infarct size were observed.
Recent studies have suggested there is no role for routine
se of thrombectomy or embolic protection in AMI. In the
REMIAR (Protection from Distal Embolization in High-
isk Patients With Acute ST-Segment Elevation Myocar-
ial Infarction) trial, use of the SpideRx filter (ev3, Plym-
uth, Minnesota) during PCI had no benefit on the extent
f ST-segment resolution, myocardial blush, EF, or clinical
utcomes (26). Similar results were found in a larger study
f 626 patients using the FilterWire device (27). De Luca
t al. published a meta-analysis of 21 trials of devices
esigned to prevent distal embolization during mechanical
eperfusion (28). Among 3,721 patients, use of adjunctive
evices was associated with better myocardial perfusion and
ess embolization; however, there was no impact on survival.
ne important issue with many of these earlier studies has
een defining which patients have significant thrombus
urden, particularly when the vessel is totally occluded. In
his regard, a recent report by Sianos et al. (29) has been
nsightful. Thrombus burden was assessed in 812 STEMI
atients before and after flow was established with either a
uidewire or small balloon. Of note, only 28% of patients had
large thrombus burden after reclassification, whereas 67%
atients would have been classified in this group if baseline
ngiography alone were used to define thrombus (29).
rug-eluting stents. Results of several studies were pub-
ished in 2007. The SESAMI (Sirolimus-Eluting Stent
ersus Bare-Metal Stent in Acute Myocardial Infarction)
rial randomized 320 STEMI patients to implantation of
ither a sirolimus-eluting stent (SES) or a bare-metal stent
BMS) (30). At 1 year, the incidence of binary restenosis
the primary end point) was lower in the SES group (9.3%
s. 21.3%; p  0.032), as was the incidence of TLR and
ACE. Valgimigli et al. provided follow-up data from the
TRATEGY (Single High-Dose Bolus Tirofiban and
irolimus Eluting Stent Versus Abciximab) trial and found
he initial benefit of SES implantation was still present at 2
ears (31). However, a report of 505 STEMI patients from
he RESEARCH (Rapamycin-Eluting Stent Evaluated at
otterdam Cardiology Hospital) and T-SEARCH (Taxus-
tent Evaluated at Rotterdam Cardiology Hospital) regis-
ries concluded that use of either a SES or a paclitaxel-
luting stent (PES) was not associated with a lower rate of
ajor adverse cardiac events (MACE) at 3-year follow-up
32). Finally, Kastrati et al. (33) published a meta-analysis of
randomized trials comparing drug-eluting stents (DES)
ith BMS in 2,786 AMI patients. The DES significantly
educed the need for reintervention (hazard ratio 0.38, 95%
I 0.29 to 0.50; p  0.001). Importantly, there was no aifference in the incidence of stent thrombosis (ST), MI, or
eath between patients receiving DES or BMS.
A randomized trial comparing a titanium-nitric oxide-
oated stent versus PES in 425 AMI patients was reported
34). At 1 year, the primary end point MACE was similar
n both arms (10.3% vs. 12.8%; p  0.5), but there was a
ower incidence of ST in the titanium-nitric oxide stent
roup.
ell-based cardiac repair. The REPAIR AMI (Reinfu-
ion of Enriched Progenitor Cells and Infarct Remodeling)
tudy demonstrated that intracoronary bone marrow cell
BMC) infusion improved EF. A Doppler substudy in 58 of
04 patients found that vessels treated with BMC infusion
ad a 90% increase in coronary flow reserve, resulting in
ormalization by 4 months (p  0.005 compared with
lacebo) (35), suggesting that BMC infusion induces heal-
ng of damaged endothelium and preservation of microvas-
ular function.
Leone et al. (36) randomized 41 patients with large
nterior wall MI (EF 50%) to granulocyte-specific
olony-stimulating factor (G-CSF) injections for 5 days
n  14) versus control (n  27). In this small series,
-CSF prevented LV dilatation and improved EF (36).
onversely, other studies have found no benefit of G-CSF
37). To investigate this lack of benefit, Ripa et al. (38)
uantified and characterized the types of cells mobilized
y G-CSF in the STEMMI (Stem Cells in Myocardial
nfarction) trial. They found a lower ratio of potentially
eneficial mesenchymal stem cells to the number of
eukocytes and an inverse relationship between mesen-
hymal stem cells and EF.
ardiogenic shock. Systemic inflammation, including
eneration of excess nitric oxide, is believed to contribute to
he pathogenesis of persistent cardiogenic shock in AMI
atients. The TRIUMPH (Tilarginine Acetate Injection in
Randomized lnternational Study in Unstable MI Patients
ith Cardiogenic Shock) trial was designed to examine the
ffect of nitric oxide synthase inhibition with tilarginine
cetate on 30-day mortality; however, the study was termi-
ated after enrollment of 398 patients (planned 658 pa-
ients) based on a pre-specified futility analysis (mortality
8% tilarginine, 42% placebo) (39). In another study,
dmission hemoglobin was found to be an independent
redictor of 1-year mortality in shock patients (40).
cute Coronary Syndromes
he ACC/AHA guidelines for acute coronary syndromes
ACS) were updated in 2007 (41). Notable changes include
ore emphasis on use of troponin as the dominant cardiac
iomarker, earlier clinical evaluation to reduce treatment
elay, B-type natriuretic peptide to supplement risk assess-
ent, use of multislice computerized tomography angiog-
aphy and cardiac magnetic resonance imaging, addition of
ondaparinux and bivalirudin as alternatives to unfraction-
ted heparin, and more support for thienopyridine use,
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Year in Interventional Cardiology June 17, 2008:2355–69ncluding upstream use and longer administration. A con-
ensus has emerged that early PCI use results in favorable
utcomes, especially in high-risk patients. On the other
and, results of the ICTUS (Invasive Versus Conservative
reatment in Unstable Coronary Syndromes) trial suggest
hat an initial conservative strategy with “watchful waiting”
ay be considered in stabilized low-risk patients (42). An
HA scientific statement discussed the value of PCI in the
lderly (greater absolute and relative benefit with PCI) (43).
nfortunately, the elderly also have a greater likelihood of
leeding complications. Insight into U.S. practice patterns
as provided from the CRUSADE (Can Rapid risk strat-
fication of Unstable angina patients Suppress ADverse
utcomes with Early implementation of the ACC/AHA
uidelines) registry on 82,924 patients with non-STEMI
reated from 2002 to 2005 (44). During this time, PCI use
ncreased from 38% to 52% of cases. In addition, PCI use in
atients with 3-vessel disease increased by 9% and coronary
rtery bypass graft (CABG) use decreased by the same
xtent. The clinical sequelae of bleeding after PCI were
ighlighted in a substudy of the ACUITY (Acute Cathe-
erization and Urgent Intervention Triage Strategy) trial
45). These authors found that patients with major hemor-
hage had higher 30-day mortality (7.3% vs. 1.2%), and
ates of ischemia and stent thrombosis were dramatically
ncreased in these patients. Bivalirudin use decreased the
isk of major hemorrhage from 5.7% to 3.0% (p  0.001).
lective PCI
CI versus medical therapy. Rarely has one clinical study
enerated so much controversy, or had such a marked and
mmediate impact on clinical practice, as the COURAGE
Clinical Outcomes Utilizing Revascularization and Ag-
ressive Drug Evaluation) trial. Boden et al. (46) screened
6,000 patients with mild stable angina and randomized
,287 (6.3%) to PCI or medical therapy (47). The primary
nd point of death or MI was the same for both groups.
ngina was significantly less at follow-up in the PCI group.
his trial corroborates previous guidelines that suggest PCI
e used only for symptomatic relief in this population.
imitations of the trial, including lack of power and high
xpected event rate were described by Kereiakes et al. (48).
he findings of the COURAGE trial were largely con-
rmed in the 5-year follow-up of the MASS (Medicine,
ngioplasty, or Surgery Study) trial in which patients
andomized to surgery, PCI, or medical therapy had similar
utcomes for PCI or medical therapy (49).
Perhaps a more powerful observation concerning treat-
ent of silent ischemia after MI was seen in the SWISSI II
Swiss Interventional Study on Silent Ischemia Type II)
rial. Erne et al. (50) randomized 201 patients with recent
I and stress-induced ischemia to PCI or medical therapy.
ercutaneous coronary intervention resulted in lower
ACE and better preservation of ventricular function. fiCI versus CABG. The final 10-year report of the BARI
Bypass Angioplasty Revascularization Investigation) trial
as published (51). Overall, no difference in mortality was
bserved between PCI and CABG patients. Patients with
reated diabetes lived longer after CABG (58% vs. 46%; p
.025). Moreover, in a retrospective registry, diabetic pa-
ients with 2- and 3-vessel disease who underwent PCI with
DES had a lower survival at 1 year compared with bypass
atients (52). This study further swings the pendulum
oward surgery for multivessel diabetic patients.
utcomes research. In 2007, there were several reports
ddressing clinical outcomes after PCI. Singh et al. (53)
rovided long-term outcome data on 24,410 PCI proce-
ures performed at the Mayo Clinic over 25 years. Signif-
cant reductions in in-hospital mortality and need for
mergency bypass surgery were observed over time. In
ddition, long-term risk-adjusted clinical outcomes, includ-
ng survival, were significantly improved over the 25-year
eriod.
Kansagra et al. (54) studied trends in operator and
ospital volume and outcomes in 452,404 patients under-
oing PCI in Florida and New York from 1996 to 2001.
he risk-adjusted end point of mortality and emergency
ABG decreased over the time period from 2.8% to 1.6%,
ith the lowest incidence of death/CABG observed with
perators performing 75 PCI procedures at hospitals with
400 procedures.
Anderson et al. (55) provided a report on the usefulness
f the American College of Cardiology-National Cardio-
ascular Data Registry (ACC-NCDR) risk-adjustment
odel to predict in-hospital mortality across the 4 classes of
CI indication (classes I, IIa, IIb, and III). The incidence of
bserved major cardiovascular complications increased from
lass I to class III. Estimated mortalities for each class using
he ACC-NCDR risk model were close to observed values
nd were similar to estimates derived using the Michigan
nd New York State risk models.
Feldman et al. (56) reported outcome data from 47,020
atients in the New York State Angioplasty Registry com-
aring those who underwent ad hoc versus staged PCI. The
ncidence of in-hospital mortality, MACE, and renal failure
as similar in both groups, suggesting the strategy of ad hoc
CI is safe in contemporary practice.
Although primary PCI may be performed at hospitals
ithout cardiac surgical backup, there has been controversy
bout performing elective PCI at hospitals without on-site
urgery. Dehmer et al. (57) examined the frequency of PCI
t facilities without on-site surgery in the ACC-NCDR.
rom 2001 to 2005, there was a marked increase from 3.2%
o 16% in the number of centers performing PCI without
ackup. Of note, there was a significant increase in the
umber of elective PCI procedures, as well as nonelective
ases, at facilities without surgical backup.
Recently, there has been debate about the appropriateness of
pecialty care cardiac hospitals. In a study of Medicare bene-
ciaries, Nallamothu et al. (58) compared the population-
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June 17, 2008:2355–69 Year in Interventional Cardiologyased rates of coronary revascularization after opening of a
ardiac hospital. Hospital referral regions (HRR) with open-
ng of a cardiac hospital had a 2-fold higher number of
evascularization procedures 4 years after opening, com-
ared with HRRs where new cardiac programs opened at a
eneral hospital or with HRRs with no new program.
In other reports, baseline anemia was found to be an
ndependent predictor of mortality and adverse clinical
utcomes after PCI (59,60).
ame-day discharge. Heyde et al. (61) evaluated the safety
f same-day discharge in 800 patients undergoing elective
CI via the femoral approach (5- or 6-F). Four hours after
CI, patients were triaged as suitable for early discharge or
ot (80% were considered to be stable for early discharge).
verall, the primary end point (death, MI, CABG, repeat
CI, or puncture-related complications) occurred in 2.2% of
ame-day discharge patients and 4.2% of overnight-stay
atients, suggesting that the early discharge strategy may be
afe in carefully selected patients.
ifurcation and intermediate lesions. Percutaneous treat-
ent of bifurcation lesions remains challenging. In a mul-
icenter registry, Tsuchikane et al. (62) used directional
oronary atherectomy before DES implantation and re-
orted a low rate of angiographic restenosis at 9 months
main branch 1.1%, side-branch 3.4%) and MACE. Grube
t al. (63) reported results of a novel self-expanding drug-
luting bifurcation stent (Axxess Plus, Devax, Irvine, Cali-
ornia). Procedural success with the stent was 90%, and
n-stent late loss was 0.09 mm.
Pijls et al. (64) presented 5-year clinical follow-up of the
EFER (Deferral Versus Performance of Percutaneous
oronary Angioplasty in Patients Without Documented
schemia) trial. Among patients with a fractional flow
eserve (FFR) of 0.75, clinical outcome was excellent,
ith no difference in event-free survival between those who
ere assigned to deferral or performance of PCI (80% vs.
3%; p  0.52). Readers requiring more in-depth study on
ssessment of intermediate coronary lesions with FFR and
ntravascular ultrasound (IVUS) should refer to a compre-
ensive review published this past year (65).
istal embolization. Several articles published in 2007
nvestigated the pathophysiology of distal embolization
uring PCI. Bahrmann et al. (66) reported on use of an
ntracoronary Doppler guidewire for real-time detection of
oronary embolization. Patients with periprocedural myo-
ecrosis had a higher frequency of microembolization dur-
ng PCI. Kawamoto et al. (67) extended these observations
nd found that the risk of embolization was related to the
resence of necrotic core assessed with virtual histology
ntravascular ultrasound. Among patients with STEMI,
awaguchi et al. (68) demonstrated that the volume of the
ecrotic core was significantly related to the risk of ST-
egment re-elevation during primary PCI. Selvanayagam
t al. (69) used cardiac magnetic resonance imaging to assess
he effect of embolization on myocardial perfusion reserve mndex and found that 21 out of 40 patients demonstrated
ew distal hyperenhancement after PCI.
ES
ate stent thrombosis. Over the past year, there have been
n enormous number of publications comparing DES with
MS, confirming the benefits of reduction in restenosis and
VR but also calling attention to a small increased risk of
ate ST after DES implantation. Several scientific reports,
eview articles, and editorials have described the scope of the
roblem (70–77). A comprehensive review of these studies
78) concluded that: 1) ST is an infrequent but very severe
omplication of both BMS and DES; 2) during 4 years of
ollow-up from randomized trials comparing DES and
MS, there is no difference in overall ST frequency,
lthough the time course differs, with an excess of ST late
fter DES implant; 3) despite this relative imbalance, no
ifferences in the end points of death or death/MI between
ES and BMS are observed; and 4) longer-term follow-up
f these patients as well as larger datasets are required to
ully study this issue.
ECHANISMS OF DES THROMBOSIS. Finn et al. (79) re-
orted data from 81 human autopsies of DES, of which 28
esions were found to have ST. The most powerful predictor
f ST was lack of endothelialization, particularly the ratio of
ncovered struts to total struts. Similarly, Awata et al. (80)
ompared serial angioscopic findings from 17 patients treated
ith SES with 11 patients treated with BMS. Neointimal
overage was typically complete by 3 to 6 months after BMS;
owever, SES-treated vessels had thrombi and yellow plaques
isualized even 2 years after implantation.
The exact mechanism of delayed endothelialization is
nknown. Cook et al. (81) reported IVUS data from 13
atients with DES thrombosis compared with 144 patients
ho had routine IVUS follow-up but no ST. Stent throm-
osis occurred more frequently with long lesions, multiple
tents, or overlapping stents. Although the size of the
eference vessel was nearly identical between groups, in
atients with ST the cross-sectional area of the external
lastic membrane was significantly larger at the stent site,
uggesting that positive remodeling may have led to incom-
lete stent apposition. Another contributing factor to DES
hrombosis may be abnormal vasomotor function of the
oronary. Obata et al. (82) studied 25 patients with AMI
ue to left anterior descending artery occlusion treated with
ES (n 13) or BMS (n 16). Two weeks after AMI, the
esponse to acetylcholine was diminished in vessels treated
ith SES, suggesting endothelium-dependent vasomotor
ysfunction.
REVENTION OF DES THROMBOSIS. Two additional studies
n 2007 noted the strong association of DES thrombosis
ith discontinuation of thienopyridine therapy (83,84). A
cientific advisory committee was convened to make recom-
endations for dual antiplatelet therapy after DES (85). A
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Year in Interventional Cardiology June 17, 2008:2355–69inimum of 12 months’ dual antiplatelet therapy was
ecommended for any patient receiving a DES (Table 1),
nd there was consensus agreement to postpone elective
urgery for at least 1 year after DES (86). Dual antiplatelet
herapy beyond 1 year is recommended by some, especially
f patient and lesion characteristics predict DES thrombosis.
isenstein et al. (87) confirmed the potential benefits of
rolonged clopidogrel use after DES, with reduction in the
isk of death or MI out to 24 months. In addition to high
lopidogrel loading doses (600 mg), one may consider a
igher maintenance dose (150 mg) in diabetics and patients
ho may be clopidogrel resistant (135).
linical outcomes after DES. RANDOMIZED TRIALS. Sev-
ral meta-analyses (88–93) have described long-term clinical
utcomes from randomized trials of DES (Table 2). All
eports demonstrate no difference in long-term mortality or
verall ST between DES and BMS. Stettler et al. (92)
onducted a meta-analysis of all 38 trials (18,023 patients)
revention of Premature Discontinuationf Dual A tiplatelet Therapy in DES Patients
Table 1 Prevention of Premature Discontinuationof Dual Antiplatelet Therapy in DES Patients
AHA/ACC/SCAI/ACS/ADA Science Advisory Recommendations (85)
12 months dual antiplatelet therapy after DES.
Patient and HCP education about hazards of premature discontinuation.
Postpone elective surgery for 1 year.
If not possible, consider continuing aspirin during post-operative period.
Avoid DES in patients unlikely to comply with 12 months of thienopyridine
therapy.
ES  drug-eluting stent; HCP  health care provider.
eta-Analyses of Randomized DES Trials in 2007
Table 2 Meta-Analyses of Randomized DES Trials in 2007
Reference Indication Randomized Trials (n
Spaulding et al. (88) On-label SES vs. BMS 4
Stone et al. (89) On-label SES vs. BMS
PES vs. BMS
9
Kastrati et al. (90) On- and off-label SES vs. BMS 14
Moreno et al. (91) On- and off-label All DES available in
Europe vs. BMS
25
Stettler et al. (92) On- and off-label SES vs. BMS
PES vs. BMS
SES vs. PES
38
Schömig et al. (93) On- and off-label SES vs. PES 16MS bare-metal stent; DES drug-eluting stent; HR hazard ratio; MImyocardial infarction; PES
evascularization; TVR  target vessel revascularization.hich prospectively randomized patients to DES, including
rials of primary PCI and off-label indications. At 4-year
ollow-up, mortality and the risk of ST was similar between
ES and BMS. Interestingly, SES were associated with a
ignificant reduction in the risk of MI compared with BMS
hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.66 to
.97; p  0.03). Moreover, SES seemed to be clinically better
han PES in reducing target lesion revascularization (TLR)
HR 0.70; p 0.0021), MI (HR 0.83; p 0.045), and late ST
p  0.041).
EGISTRIES. Several large multicenter or national registries
omparing DES with BMS have confirmed the safety of
ES (94–102). Although the original SCAAR (Swedish
oronary Angiography and Angioplasty Registry) publica-
ion suggested an increase in late events in DES-treated
atients (98), a larger more updated report showed a 50%
eduction in restenosis and similar long-term mortality
ompared with BMS (99). Furthermore, there was a signif-
cant reduction in MI/death within the first 6 months after
ES. Similarly, registries from Canada, Denmark, Italy,
nd the U.S. have demonstrated that use of DES was
ssociated with reduced target vessel revascularization
TVR) with either superior or similar rates of death and MI
ompared with BMS (Table 3).
ff-label use of DES. Beohar et al. (103) reported a
ulticenter registry of 5,541 patients receiving DES, of
hich 47% were for off-label or untested indications. The
0-day risk of death, MI, or ST and 1-year rate of TVR was
ignificantly higher when DES was used off-label compared
Patients (n) Follow-Up (yrs) Results
1,748 4 No difference in death, MI, ST.
5,261 4 No difference in death, MI, ST at 4 yrs.
Between 1 and 4 yrs, higher ST with
SES (0.6% vs. 0%; p  0.025) and
PES (0.7% vs. 2%; p  0.028)
compared with BMS.2TVR with SES
(12.1% vs. 27.5%; HR 0.38;
p  0.001) and PES (17.2% vs.
24.7%; HR 0.62; p  0.001)
compared with BMS.
4,958 1–5 No difference in death, death or MI, ST.
After 1 yr, slight1 ST with SES vs.
BMS. Significant2 TVR with SES.
9,791 0.5–1 Significant2 MI (3.3% vs. 4.2%; HR
0.79; p  0.03) with DES vs. BMS.
18,023 1–4 Mortality similar between SES, PES,
BMS. SES:2 MI vs. BMS (HR 0.81;
p  0.03) and vs. PES (HR 0.83;
p  0.045). SES:2 TLR vs. PES (HR
0.70; p  0.0021). PES:1 late ST
vs. BMS (HR 2.11; p  0.017) and
vs. SES (HR 1.85; p  0.041).
8,695 1–3 SES:2 TLR (HR 0.74; p  0.001) vs.
PES. SES:2 ST (HR 0.66; p  0.02)
vs. PES. SES:2 MI (HR 0.84; p 
0.07) vs. PES.)paclitaxel-eluting stent; SES sirolimus-eluting stent; ST stent thrombosis; TLR target lesion
w
w
r
h
m
c
“
o
s
f
l
g
d
a
o
o
r
s
l
D
t
A
d
U
r
c
(
c
f
(
p
l
s
d
i
t
t
a
d
s
M
v
I
A
i
fl
P
r
a
p
U
t
P
a
L
(
S
r
(
t
r
g
(
L
*
2361JACC Vol. 51, No. 24, 2008 Dixon et al.
June 17, 2008:2355–69 Year in Interventional Cardiologyith approved indications; however, absolute event rates
ere quite low. Win et al. (104) reported a multicenter
egistry of 3,323 patients treated with DES, of whom 55%
ad at least 1 off-label indication. They noted similar
ortality but a higher risk of MI, ST, and TVR in off-label
ompared with FDA-approved DES indications. These
off-label” patients are a high-risk population with numer-
us comorbidities, unfavorable lesion morphology, and un-
table clinical presentations, and are expected to have less
avorable outcomes after either BMS or DES. However,
arge real-world registries including off-label applications
enerally demonstrated that DES was associated with re-
uced TVR with either superior or similar rates of death
nd MI compared with BMS (Table 3).
Colombo and Chieffo (105) provided an excellent review
f publications addressing off-label use of DES. Based on
bservational and case-controlled series as well as small
andomized trials, they concluded that in some lesion
ubsets (chronic occlusions, bifurcations, small vessels, long
esions, vein grafts) the data appear to support the use of
ES. They caution against the routine use of DES in
riple-vessel disease, diabetics with multivessel disease,
MI, and unprotected left main coronary artery until more
ata and longer follow-up are available.
NPROTECTED LEFT MAIN DISEASE. Chieffo et al. (106)
eported a multicenter registry in which 147 patients re-
eived DES for unprotected left main coronary artery
ULMCA) lesions (distal bifurcation lesions were ex-
luded). Procedural success was 99%, and at long-term
ollow-up (886 308 days), rates of death (3.4%) and TVR
4.7%) were low. The Sheiban et al. (107) registry of 85
atients with ULMCA treated with SES noted that 61% of
esions involved the distal bifurcation (43% received single
tent, 57% modified T or V stenting). At 2-year follow-up,
arge Registries of Drug-Eluting Stents in 2007
Table 3 Large Registries of Drug-Eluting Stents in 2007
Reference Country Patients (n) Follow-Up (y
DES vs. BMS
NHLBI (94) U.S. 1,460 DES
1,763 BMS
1
Marzocchi et al. (95) Italy 3,064 DES
7,565 BMS
2
Jensen et al. (96) Denmark 3,548 DES
8,847 BMS
1.25
Tu et al. (97) Ontario 3,751 DES*
3,751 BMS*
2
SCAAR (98,99) Sweden 118,000 stents
(37,000 DES)
2–4
SES vs. PES
Daemen et al. (100) the Netherlands,
Switzerland
8,146 DES 3
Cosgrave et al. (101) Italy, Belgium 1,283 DES 1
Simonton et al. (102) U.S. 9,226 DES 0.75Propensity score matched.
CI  confidence interval; NHLBI  National Heart, Lung, and Blood Institute; RR  risk ratio; SCAAR  Sweeath occurred in only 2.4%, MI in 3.6%, and TVR
n 10.8%.
Sanmartin et al. (108) retrospectively compared 96 pa-
ients with ULMCA treated with DES with 245 patients
reated with bypass surgery. Surgically treated patients had
trend for higher combined death, stroke, and Q-wave MI
uring long-term follow-up (p  0.07). However, the
urgical group was higher risk and had longer follow-up.
oreover, TVR was higher in the DES group.
Erglis et al. (109) conducted a randomized trial of BMS
ersus PES in 103 patients with ULMCA. All PCIs were
VUS guided and used cutting balloon followed by stenting.
lthough 75% of lesions were in the distal LMCA, the
nvestigators used a single stent strategy jailing the circum-
ex. At 6 months, restenosis occurred in 22% BMS and 6%
ES patients (p  0.021), and MACE in 30% and 13%,
espectively (p  0.054).
Therefore, DES for ULMCA may be a reasonable
pproach in selected patients, but routine application is
remature. An editorial reviewing the use of stents for
LMCA addressed numerous unanswered questions and
he need to await results of the SYNTAX (Synergy Between
ercutaneous Coronary Intervention With TAXUS DES
nd Cardiac Surgery) trial (110).
ESIONS AT HIGH RISK OF RESTENOSIS. Baumgart et al.
111) reported 1-year results in 200 diabetics randomized to
ES versus BMS. In-segment restenosis was significantly
educed with SES (8.8% vs. 42.1%; p 0.0001), as were TLR
5.3% vs. 21.1%; p  0.002) and MACE (14.7% vs. 35.8%).
At 18 months’ follow-up of a prospective randomized
rial, DES were found to be cost-effective in lesions at high
isk of restenosis (vessel size 3.0 mm or saphenous vein
raft lesions) (112). In a subgroup analysis of the SIRTAX
Sirolimus-Eluting Stent Compared With Paclitaxel-
Results
DES:2 TVR (HR 0.38; p  0.001).
No difference in death, MI.
DES:2 TVR.
No difference in adjusted risk of death, MI.
DES:2 TVR by 43%.
No difference in death, MI, ST.
DES:2 TVR (7.4% vs. 10.7%; p  0.001).
DES:2 mortality (5.5% vs. 7.8%; p  0.001).
DES:2 clinical restenosis (RR 0.48, 95% CI 0.39–0.58).
DES:2 MI at 6 months (RR 0.82, 95%, CI 0.72–0.93).
Similar death, MI at long-term follow-up.
Overall ST 2.9% at 3 yrs.
Late (30 days) ST1 with PES compared with SES (1.8% vs. 1.4%; p  0.031).
No difference in TLR or MACE between SES and PES.
No difference in death, MI, TVR, or ST at 9 months between SES and PES.rs)dish Coronary Angiography and Angioplasty Registry; other abbreviations as in Tables 1 and 2.
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rial, Togni et al. (113) confirmed the benefit (reduced
ACE and TVR) of SES over PES in small vessels.
imilarly, Petronio et al. (114) found significantly reduced
eointimal hyperplasia assessed by IVUS in a randomized
rial of SES versus PES in long left anterior descending
rtery lesions.
Dibra (115) performed a meta-analysis of 4 trials, which
andomized 1,230 patients with restenosis to DES versus
ercutaneous transluminal coronary angioplasty or brachy-
herapy. Drug-eluting stents were associated with signifi-
ant reductions in TLR (odds ratio [OR] 0.35, 95% CI 0.25
o 0.49; p  0.001) and angiographic restenosis (OR 0.36,
5% CI 0.27 to 0.49; p  0.001).
On a more somber note, the only randomized trial of
ES in vein grafts showed initial benefit, but long-term
ollow-up at 32 months demonstrated loss of the initial
eduction in TLR, as well as higher mortality (29% vs. 0%;
 0.001) (116). However, given the small sample size
n  75), mortality differences may be due to chance.
ES restenosis. Drug-eluting stents have greatly reduced,
ut not eliminated, restenosis. When DES restenosis is
anaged percutaneously, it is associated with a high rate of
ACE (117). Oral medications may further reduce the
ncidence of DES restenosis. One trial randomized 274
atients treated with PES to receive celecoxib (400 mg
efore PCI and 200 mg twice daily for 6 months) versus
ontrol (118), and found reduced late loss (0.49 mm vs. 0.75
m) and TLR (5% vs. 15%; p  0.008) with celecoxib. A
arger study randomized 500 patients with long lesions
32 mm) requiring DES to cilostazol (200 mg load, 100
g twice daily for 6 months) versus control (119). The
ilostazol group had reduced late loss (0.34 mm vs. 0.51
m; p  0.001) and TLR (2.8% vs. 6.8%; p  0.036) in
his subgroup of patients at high risk of DES restenosis.
ew DES. Daemen and Serruys (120) provided an out-
tanding review of current and future DES. They discussed
ew stent platforms, including magnesium and bioabsorb-
ble stents, new coatings and polymers to reduce inflamma-
ory reactions, heparin coatings combined with SES, and
iodegradable polymers. Finally, they reviewed the drug
oatings, including new paclitaxel stents, 6 different limus-
elated antiproliferative drugs, combinations of limus drugs
ith dexamethasone or paclitaxel, and the prohealing ap-
roach using antibodies targeted at endothelial progenitor
ells.
Publications of new DES were limited in 2007. Turco
t al. (121) reported results from a prospective registry using
he Taxus Liberté stent platform (designed to be more
eliverable). Despite applications to more complex lesions,
linical outcomes and late loss were equivalent to an earlier
ohort of patients treated with the Taxus Express platform.
rbel et al. (122) reported the use of 71 bioabsorbable
agnesium stents and found early success, but late loss at 4
onths was high (1.08 mm), and by 1 year TVR was 45%. zeointimal growth and negative remodeling were the
echanisms of restenosis.
Adriaenssens et al. (123) randomized 502 patients to a
apamycin-eluting stent (RES) plus estradiol versus RES
lone (both stents were polymer free). At 1 year, late loss
nd clinical events were similar between the 2 groups.
owever, the study did not assess whether estrogen pro-
oted rapid re-endothelialization (which is the potential
enefit of estradiol) and was not powered to determine
ifferences in ST.
rachytherapy
errero et al. (124) reported 5-year follow-up of the BetAce
rial of brachytherapy for treatment of de novo lesions.
lthough brachytherapy reduced the need for TVR at 6
onths, this benefit was not sustained. Lee et al. (125)
ompared outcomes after SES versus brachytherapy for
iffuse in-stent restenosis. At 3 years, the incidence of TLR
nd MACE was significantly lower in patients treated with
ES compared with brachytherapy.
aphenous Vein Graft Disease
he PROXIMAL (Proximal Protection During Saphenous
ein Graft Intervention) trial evaluated use of proximal
mbolic protection with the Proxis Embolic Protection
ystem (St. Jude Medical, Maple Grove, Minneapolis)
126). A total of 594 patients were randomized in a
oninferiority design to either control (distal protection
henever possible) or test (proximal protection when pos-
ible, distal when not). The 30-day MACE rate was 9.2% in
he test arm and 10.0% in the control arm, suggesting that
roximal embolic protection provides similar outcomes to
istal protection devices.
Results of the AMEthyst (Assessment of the Medtronic
VE Interceptor Saphenous Vein Graft Filter System) trial,
hich evaluated the Medtronic Interceptor Plus distal filter
Medtronic, Minneapolis, Minnesota), were presented this
ast year (127). At 30 days, the primary end point MACE
ccurred in 8.0% of patients in the Interceptor arm and
.2% of patients in the control device arm (GuardWire or
ilterWire) (p  0.027 for noninferiority), suggesting that
his novel filter provides a similar degree of protection to the
ther approved devices.
Despite the benefit of embolic protection, recent data
rom the ACC-NCDR are sobering (128). Among 19,546
atients undergoing vein graft intervention, an embolic
rotection device was used in only 22%. Use of an embolic
rotection device was associated with a lower incidence of
o-reflow (OR 0.68; p  0.032) but no difference in
n-hospital mortality. The universal occurrence of distal
mbolization in vein grafts was highlighted in a report from
an Gaal et al. (129) in which 57 out of 58 patients were
ound to have visible debris after PCI. Moreover, emboli-
ation was not predicted by baseline clinical or angiographic
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June 17, 2008:2355–69 Year in Interventional Cardiologyariables, thus underscoring the importance of embolic
rotection in vein graft intervention.
harmacotherapy
lopidogrel. Inadequate response to antiplatelet therapy
as nicely summarized in a review article (130). Mahmud
t al. (131) investigated 150 patients treated with eptifi-
atide and found inadequate platelet inhibition (PI) in 61%
f patients after a single bolus, and in 36% after a double
olus. A fibrinogen level 75 mg/dl was a strong predictor
f inadequate PI.
Bliden et al. (132) studied 100 patients treated with
spirin and clopidogrel for more than 1 month before PCI
nd found a strong association between post-PCI ischemic
vents and high platelet aggregation. Similarly, Buonamici
t al. (133) found that 13% of 804 patients treated with 600
g clopidogrel had inadequate PI, and those patients
uffered an 8.6% incidence of ST within 6 months. Campo
t al. (134) performed platelet aggregation studies in 143
atients taking clopidogrel, and then repeated studies after
rossing over to ticlopidine. Inadequate PI to either clopi-
ogrel or ticlopidine at steady state was common, but
onresponse to both drugs was infrequent (3.5%), suggest-
ng that inadequate PI is drug specific rather than class
pecific. Angiolillo et al. (135) randomized 40 patients with
ype 2 diabetes mellitus (a disease known to have inadequate
I) to clopidogrel maintenance doses of 75 mg versus 150
g/day. Although the high-dose group had significant (p
.002) improvement in PI, 60% of diabetics still had
uboptimal clopidogrel response.
Prasugrel, a new thienopyridine with greater and more
onsistent PI, was compared with clopidogrel in 13,608
CS patients undergoing PCI (136). The primary end
oint of cardiovascular death, MI, or stroke was improved
ith prasugrel (9.9% vs. 12.1%; p  0.001), as was MI
7.4% vs. 9.7%; p  0.001), urgent TVR (2.5% vs. 3.7%;
 0.001), and ST (1.1% vs. 2.4%; p  0.001). However,
ife-threatening bleeding was increased (1.4% vs. 0.9%; p 
.01), and patients with previous stroke had net clinical
arm from prasugrel.
lycoprotein IIb/IIIa receptor inhibitor. To determine
hether the duration of glycoprotein IIb/IIIa inhibitor
nfusion could be shortened after uncomplicated PCI, the
RIEF-PCI (Brief Infusion of Eptifibatide Following PCI)
Major Outcomes of the ACUITY Trial
Table 4 Major Outcomes of the ACUITY Tria
Study
UFH/Enoxaparin  IIb/IIIa
(n  2,561)
Ischemia 8%
Major bleeding 7%
Transfusion 3%
TIMI major bleed 2%
TIMI minor bleed 8%
Data from Stone et al. (139). *Comparison between bivalrudin and he
ACUITY  Acute Catheterization and Urgent Intervention Triage Strateg
Myocardial Infarction; UFH  unfractionated heparin.tudy randomized 624 patients (45% ACS, 70% clopidogrel
re-treatment) to either a 2-h or a standard 18-h infusion of
ptifibatide (137). The primary end point, incidence of
schemic injury, was 30.1% in the short group and 28.3% in
he standard group. Major bleeding was less frequent in the
hort group. These data suggest that the infusion of eptifi-
atide can be abbreviated after successful PCI.
The EVA-AMI (Eptifibatide Versus Abciximab in Pri-
ary PCI for Acute ST Elevation Myocardial Infarction)
tudy randomized 429 STEMI patients undergoing primary
CI to receive either abciximab or eptifibatide (138). There
as no significant difference in the primary end point, the
xtent of ST-segment resolution 60 min after PCI.
ntithrombin therapy. Stone et al. (139) compared use of
ivalirudin and unfractionated heparin or enoxaparin for
atients undergoing PCI. Outcomes, summarized in Table
, suggest no difference in ischemic end points but a major
ecline in risk of bleeding events for patients treated with
ivalirudin. Of note, however, subgroup analysis showed a
mall increase in ischemic events in patients who were not
re-treated with clopidogrel. In a planned subgroup analysis
f the ACUITY trial, Stone described compared upstream
ersus intraprocedural glycoprotein IIb/IIIa use (140). Up-
tream use did not decrease ischemic events (7.7% vs. 4.1%;
 NS), but increased major bleeding (6.1% vs. 4.9%;
 0.001). Feit et al. (141) further highlighted the
mportance of bleeding complications in a subanalysis of the
EPLACE (Randomized Evaluation of PCI Linking
ngiomax to Reduced Clinical Events) 2 trial. In this
eport, 3.2% of patients had major hemorrhage after PCI,
nd 1-year mortality was significantly higher for patients
ith major bleeding (8.7% vs. 1.9%; p  0.001).
Other new anticoagulation regimens during PCI were
ested. Mehta et al. (142) analyzed 6,238 PCI patients
reated with fondaparinux versus enoxaparin in the
ASIS-5 trial. Major bleeding was reduced by fondapa-
inux use (2.4% vs. 5.1%; p  0.00001); however, catheter
hrombosis was more frequent with fondaparinux (0.9% vs.
.4%). Another new direct factor Xa inhibitor, otamixaban,
as tested in 947 patients in the SEPIA-PCI (Study to
valuate the Pharmacodynamics, the Safety and Tolerabil-
ty, and the Pharmacokinetics of Several Intravenous Reg-
mens of the Factor Xa Inhibitor Otamixaban (XRP0673),
n Comparison to Intravenous Unfractionated Heparin in
irudin  IIb/IIIa
n  2,609)
Bivalirudin Alone
(n  2,619) p Value*
9% 9% 0.45
8% 4% 0.0001
4% 2% 0.002
2% 0.8% 0.0001
8% 4% 0.0001
unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitor.l
Bival
(
parin (
y; IIb/IIIa  glycoprotein IIb/IIIa inhibitor; TIMI  Thrombolysis In
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ntervention) trial (143). The agent had efficacy at higher
oses, but catheter thrombosis was also reported in patients
reated at low dosages without IIb/IIIa inhibitors. Both the
ASIS and the SEPIA-PCI trials highlight a major, pitfall
f factor Xa inhibitor use during PCI.
Finally, Teirstein’s group reported a novel anticoagulation
egimen in the REMOVE trial (144). These investigators
sed a triple antiplatelet therapy (aspirin, clopidogrel, epti-
batide) and randomized patients to unfractionated heparin
ersus no heparin. Bleeding (as assessed by the Landefeld
leeding index) was reduced in the no-heparin group (3.0%
s. 3.7%; p  0.03). Owing to the small sample size, larger
onfirmatory trials of this approach will be required.
tatins. Pre-treatment with high-dose statins appear to
ave a protective effect in patients undergoing PCI. The
RMYDA-ACS (Atorvastatin for Reduction of Myocar-
ial Damage During Angioplasty) trial randomly assigned
71 patients with a non–ST-segment elevation ACS to
re-treatment with atorvastatin (80 mg 12 h before PCI) or
lacebo (145). In this small trial, patients in the atorvastatin
rm had a significantly lower incidence of 30-day MACE
5% vs. 17%; p  0.01), driven mostly by a lower incidence
f MI within the first 24 h.
ontrast Nephropathy
revention of contrast-induced nephropathy (CIN) remains
n important focus of ongoing research. The CARE (Car-
iac Angiography in Renally Impaired Patients) trial com-
ared the effect of iopamidol (low osmolar) and iodixanol
iso-osmolar) in 482 patients with baseline creatinine clear-
nce 60 ml/min (146). There was no difference in the
ncidence of CIN between the low-osmolar and iso-osmolar
gents (4.4% vs. 6.7%; p  0.39).
rials Evaluating Use of Sodium Bicarbonate Infusion for Prevention
Table 5 Trials Evaluating Use of Sodium Bicarbonate Infusion f
Study Study Design No. of P
MEENA (147) Randomized to sodium bicarbonate or saline
(stratified by NAC and diabetes)
353,
REMEDIAL (148) Randomized to saline  NAC, bicarbonate  NAC,
or normal saline  ascorbic acid  NAC
326,
RENO (149) Randomized to bicarbonate  NAC started 1 h
before contrast injection, or normal saline 
NAC after PCI
111,
Masuda et al. (150) Randomized to sodium bicarbonate or normal
saline
59, siHF  congestive heart failure; CIN  contrast-induced nephropathy; ClCr  creatinine clearance; eGFR
ollowing Contrast Media Administration Trial; RENO  Registry Novoste; sCr  serum creatinine.In 2007, there were 4 studies investigating the effect of
odium bicarbonate infusion for prevention of CIN (147–
50) (Table 5). In the largest trial, bicarbonate infusion had
o effect on the incidence of CIN (147). Three other
tudies, however, demonstrated a lower incidence of CIN
ith bicarbonate (148–150). Until further data are forth-
oming, it seems reasonable to use bicarbonate infusion in
atients at risk for CIN, given the ease of this approach and
ack of alternative protective therapies.
For patients with more severe chronic renal failure, prophy-
actic hemodialysis appears to be a useful strategy. Lee et al.
151) randomized 82 patients with serum creatinine 3.5
g/dl to hemodialysis (started as soon as possible after angiog-
aphy, duration 4 h) or normal saline alone. Patients treated
ith prophylactic hemodialysis had a smaller change in renal
unction at 72 h and a significantly lower need for temporary or
ermanent renal replacement therapy.
Laskey et al. (152) reported a novel technique to predict the
isk of an increase in serum creatinine after PCI based on the
atio of contrast media to creatine clearance (V/CrCl). In 3,179
atients undergoing PCI, a V/CrCl ratio 3.7 was identified
s a significant independent predictor of post-PCI creatinine
ncrease (OR 3.84, 95% CI 2.0 to 7.3; p 0.001). This useful
ndex can be applied to estimate the maximum amount of
ontrast for a patient, above which there is a likelihood of
eveloping acute deterioration of renal function.
tructural Heart Disease
ercutaneous aortic valve replacement. Further clinical
rial experience with the Edwards pericardial stent valve was
eported by Webb et al. (153) and Walther et al. (154).
ebb reported the Vancouver experience on 50 patients
reated via the transfemoral approach. The 30-day mortality
as 12%. No structural deterioration in valve function was
ontrast-Induced Nephropathy in 2007
evention of Contrast-Induced Nephropathy in 2007
s, Sites Major Inclusion Criteria Results
center Patients undergoing coronary
angiography. eGFR 60
ml/min  one risk factor
(diabetes, CHF,
hypertension, age 75).
No difference in rate of CIN (25%
reduction GFR within 4 days) in
bicarbonate (13.6%) or saline
(13.5%) groups.
rs Patients undergoing elective
coronary or peripheral
procedures. Serum
creatinine 2.0 mg/dl or
eGFR 40 ml/min.
Lower incidence of CIN (25%1 sCr
at 48 h) with bicarbonate (1.9%)
compared with saline (9.9%) or
ascorbic acid (10.3%) groups.
center ACS patients undergoing
emergency PCI. No
inclusion criteria based on
GFR (mean sCr 1.0 mg/dl).
Lower incidence of CIN (0.5 mg/dl
1 sCr at 3 days) with bicarbonate
(1.8%) compared with saline
(21.8%) group.
nter Patients undergoing
emergency catheterization.
Serum creatinine 1.1
mg/dl or ClCr 60 ml/min.
No NAC.
Lower incidence of CIN with
bicarbonate (7% vs. 35%; p  0.01).of C
or Pr
atient
single
2 cente
single
ngle ce estimated glomerular filtration rate; NAC  N-acetylcysteine; REMEDIAL  Renal Insufficiency
o
m
a
s
t
P
e
o
s
y
1

p
c
s
e
e
w
t
H
r
A
r
c
p
t
n
i
a
c
9
i
P
C
D
T
d
t
i
c
d
i
3
v
b
a
s
T
l
i
P
f
k
A
d
i
a
a
b
3
T
r
t
i
R
s
R
R
2365JACC Vol. 51, No. 24, 2008 Dixon et al.
June 17, 2008:2355–69 Year in Interventional Cardiologybserved at 1 year. Walther et al. (154) reported the surgical
ulticenter experience in 59 patients treated by a transapical
pproach. The in-hospital mortality was 13.6%. These data
erve as prelude to pivotal U.S. FDA approval trials with
his technology.
atent foramen ovale and atrial septal defect. Handke
t al. (155) provided a report suggesting that patent foramen
vale (PFO) has a strong association with cryptogenic
troke in both young and old patients. For patients 55
ears old with cryptogenic stroke, 44% had a PFO versus
4% in patients with a known cause of stroke. For patients
55 years old, PFO was also more frequent (28% vs. 12%;
  0.001). These data continue to fuel interest in the
oncept that PFO closure may decrease risk of embolic
troke.
Devices for transcatheter closure of PFO continue to be
valuated. Jones et al. (156) reported the multicenter U.S.
xperience in 119 patients with atrial septal defect treated
ith the Helex septal occluder device. Radiofrequency
hermal coaptation of PFO was tested in a porcine model by
ara et al. (157). Sievert et al. (158) tested another
adiofrequency device in 30 patients.
trial appendage and other devices. Sick et al. (159)
eported use of the Watchman left atrial appendage oc-
luder system (Atritech, Plymouth, Minnesota). Sixty-six
atients who were candidates for systemic anticoagulation were
reated and followed-up for 740 days. There were 2
ondevice-related deaths, 2 patients with tamponade after
mplantation, and 2 patients had a transient ischemic attack
t follow-up. Banai et al. (160) reported implantation of a
oronary sinus reducer to treat refractory angina. Six out of
 patients had an improvement in angina and exercise-
nduced ischemia.
eripheral Vascular Disease
arotid disease. In 2007, a Clinical Expert Consensus
ocument on carotid artery stenting was published (161).
he document includes recommendations on evaluation,
iagnostic imaging, medical therapy, carotid revasculariza-
ion, and credentialing. Van der Heyden et al. (162)
nvestigated the use of carotid stenting before planned
ardiac surgery in patients with severe asymptomatic carotid
isease. Procedural success was 97.7%, and there was a low
ncidence of death and stroke from time of carotid stent to
0 days after surgery (4.8%), suggesting that this is a
aluable alternative treatment option in patients with com-
ined carotid and cardiac disease. Kao et al. (163) provided
 report on the feasibility of endovascular recanalization for
ymptomatic internal carotid artery occlusion in 30 patients.
echnical success was 73%. Finally, Goldstein (164) pub-
ished a comprehensive review on the treatment of acute
schemic stroke.
eripheral disease. The optimal treatment of superficial
emoral artery (SFA) disease has been controversial. Kran-
enberg et al. (165) published results of the FAST (Femoralrtery Stenting Trial), in which 244 patients with SFA
isease and chronic limb ischemia were randomized to
mplantation of a single nitinol stent or balloon angioplasty
lone. At 1 year, the primary end point of ultrasound-
ssessed binary restenosis was not statistically different
etween the treatment arms (38.1% for angioplasty vs.
1.7% for stent; p  0.37), nor was there any difference in
LR. Finally, Mahmud et al. (166) published an excellent
eview article on the current role of endovascular therapy in
he management of subclavian, carotid, renal, aortoiliac, and
nfrainguinal disease.
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